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Drug and nucleic acid delivery by means of nanoparticle vectorization is a buzzing field in 
nanomedicine, with the ultimate goal being the achievement of a therapeutic outcome supported by 
an efficient delivery to the targeted cell population that does not compromise safety issues. Despite 
all the hype and progress that already spans several decades, still few strategies overcame the valley 
of death and reached the bedside. Many of the proposed systems have successfully conquered a 
number of hurdles in vitro and/or in pre-clinical animal models, nonetheless have failed in relevant 
clinical context. How can we (im)prove the efficiency and safety of nanoparticle delivery throughout 
the organism? Most of the work done to answer this central question is based on the evaluation of 
the interaction of nanoparticles with cells and tissues, mostly focusing on increasing nanoparticle 
internalization efficiency, and outcome assessment. It is well established that by tailoring the 
nanoparticle physicochemical properties such as size, shape, surface charge and composition, one 
can tune cell–nanoparticle interaction and uptake pathways. However, generalization of the 
assumptions related to the nanoparticles and their internalization pathways is dangerous since there 
are numerous exceptions to the proposed ‘rules’ [1]. On the other end of the process, by evaluating 
the outcome of nanoparticle administration, we can infer about the therapeutic efficiency of the 
proposed system and, at times, address safety issues. But the intracellular processes that occur in-
between nanoparticle cellular entry and biological response remain, at large, a black box. 
Additionally, few studies have examined the intracellular process of vector degradation or excretion 
[2,3]. In other words, in most cases neither we know the exact pathway and fate of the nanoparticles 
upon cellular entry, nor if their intracellular distribution is related with beneficial or adverse effects to 
the cell other than the expected outcome. Moreover, the information of the number of nanoparticles 
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that reach a cell, as well as the number of nanoparticles that in fact efficiently deliver its cargo is, for 
the large majority of systems, unknown. Should one decide on the future of a proposed vector 
material or nanoparticle system solely based on such intangible information? 
Making visible the invisible 
Classical bioimaging methods applied in the study of nanoparticles in a cellular context are based on 
the fluorescent labeling of the nanoparticles, as well as of particular intracellular compartments, and 
the use of fluorescence microscopy, mostly laser scanning confocal microscopy, combined with flow 
cytometry [3]. These techniques can be complemented with electron transmission microscopy when 
the vectors have specific electron‐optical contrast features or can be labeled with contrast agents [4]. 
However, the information that can be extracted from these analyses is incomplete. Confocal 
microscopy is widely used but the resolution limit is an obstacle when imaging particles below 100 
nm. Therefore, most of the studies are based on the analysis of nanoparticle-loaded vesicles inside 
the cell. In turn, electron microscopy allows for the imaging of nanoparticles independently of their 
size but to acquire enough quantitative data for statistical analysis is laborious and time consuming, 
hindering the possibility of a high-throughput evaluation. Although highly quantitative information 
can be obtained by flow cytometry, there is no spatial resolution and one cannot define the 
intracellular position of a particle nor distinguish nanoparticle cellular association from 
internalization. Currently alternative methodologies are being explored to address such unresolved 
questions, including: spinning disk confocal microscopy to study nanoparticle uptake kinetics and 
intracellular movement, taking advantage of reduced multichannel acquisition times [5]; atomic 
force microscopy to measure the force and/or specificity of the interaction between nanoparticles 
and the plasma membrane [6,7]; fluorescence correlation spectroscopy and raster image correlation 
spectroscopy, which can be used to obtain the hydrodynamic radii of the nanoparticles when 
internalized as well as kinetic parameters such as nanoparticle the intracellular diffusion coefficient 
[8] and super-resolution systems to overcome the limitation of the optical resolution of a regular 
confocal microscope [9], though imaging depth is still a constraint when working with cells growing 
on 3D scaffolds or even tissues [10]. To increase the imaging depth the use of multiphoton 
microscopy is an alternative. Other solutions take advantage of combining different technologies 
such as correlative light and electron microscopy that relates the 3D distribution information 
obtained by confocal microscopy with the image resolution of the electron microscope for the 
analysis of single particles versus aggregates/agglomerates [11] and tip-enhanced Raman 
spectroscopy that allows a lateral resolution down to 10–20 nm giving chemical information that 
might be valuable to study also nanoparticle stability. Nevertheless, for quantification purposes all 
these techniques are quite time consuming and high-throughput platforms are emerging for a better 
quantification of internalization characteristics. In this direction, a promising solution is imaging flow 
cytometry, which combines the statistical strength of flow cytometry with image acquisition of every 
event making it possible to differentiate internalized from adsorbed nanoparticles [12,13] and even 
explore intracellular localization. 
All these techniques are normally used in combination with specific intracellular labels to address the 
nanoparticle intracellular fate or trafficking kinetics. To unravel the nanoparticle intracellular 
localization the conventional analyses focus mainly on the quantification of nanoparticle co-
localization with specific intracellular organelles involved in the different internalization pathways, 
as nanoparticle internalization either occurs by endocytic mechanisms or passive internalization (rare 
event). Additionally, one can use pharmacological inhibitors to interrupt a certain intracellular 
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pathway, as well as delete or express a mutant of a specific gene involved in the cellular uptake 
machinery. These strategies have proven to be very valuable but care must be taken when 
interpreting the obtained results. Available intracellular markers are not always exclusive for a 
specific organelle, since the endocytic pathway is a dynamic and continuous set of organelles that 
arise from a maturation process. Consequently, some membrane proteins used as markers are 
common between them [14]. Many of the available inhibitors lack specificity, blocking more than one 
pathway and are cytotoxic at the functional concentrations [15]. Last but not least, the nanoparticles 
specific entry route does not always determine their postinternalization fate and intracellular location 
[16]. Complimentary biochemical methods are used but also these rely on the use of specific 
biomarkers. Consequently, in parallel to the advance of new imaging technologies and modalities, 
several tools have been put forward to contribute to the knowledge of mechanism of nanoparticle-
mediated delivery. Fluorescent protein-based tools are now available to study nanoparticle 
properties, cellular uptake, subcellular trafficking, diffusion and stability inside the cell. Classically, 
one labels the vector and the cargo with different fluorophores to allow their tracking inside the cell 
[17]. A variation of this is the use of specific fluorophores for fluorescence resonance energy transfer 
that can capture nanoparticle intracellular dynamics [18]. Examples of other tools include: the use of 
fluorescent probes that are only active in a specific environment, that is, the reducing environment 
of the cell cytoplasm [19] or at a certain pH [20]; the application of fluorescence recovery after 
photobleaching to track nanoparticle dynamic properties inside the cell [8] and timer fluorescent 
proteins for the quantification and study of the outcome kinetics [21]. 
Chip of reality 
While still many challenges remain ahead, several studies have already contributed to a better 
understanding of nanoparticle intracellular fate and to unravel a number of bottlenecks to the 
processes of nanoparticle-based delivery. Most of these have been based on in vitro set-ups. 
Resolution and lack of sensitivity of the current in vivo bioimaging tools remain an obstacle. 
Therefore, the knowledge of nanoparticle behavior at the whole body scale is still limited to the 
evaluation of overall biodistribution/accumulation in key organs, time of clearance, inflammatory 
reaction and associated toxicity. 
In this context, current efforts are being drawn to the finding of alternative methods to animal 
experimentation, with the development of robust and predictive in vitro culture platforms that can 
more realistically mimic the in vivo conditions. Ideally, these in vitro models should fulfill several 
requisites such as recapitulate the tissue complexity – including the presence of multiple cell 
types/tissues, compartmentalization, existence of a circulatory system – be reproducible, easy to 
assemble and allow the generation of sufficient quantitative data. The use of conventional static 2D 
monolayer and 3D cell culture systems, to which tissue engineering significantly contributed, to 
assess cell–nanoparticle interaction fail to simulate in vivo conditions mainly due to the lack of 
dynamic flow. Besides the creation of gradients of (bio)molecules that do not reflect the in vivo 
conditions, static models introduce artefacts that may influence the outcomes. In the absence of flow 
nanoparticles can sediment, which directly impacts nanoparticle uptake by cells and thus influences 
the studies of nanoparticle dosage/toxicity. Recent advances in the development of dynamic 
bioreactors at the microscale level have positively contributed to this scenario. Commonly referred 
as microfluidic systems, such bioreactors allow cell, organ and even small organism cultures within 
controlled physiological flow and dynamic spatiotemporal controlled molecular gradients. Using 
such systems one can control cell–cell as well as cell–matrix interactions in addition to tissue-to-fluid 
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ratio. Microfluidic devices are fabricated in a very controlled way, taking advantage of soft 
lithography techniques and can be easily assembled with different geometries and features to fulfill 
particular needs of the tissue that is being modeled. Furthermore, these systems are normally built 
on optically transparent materials, such as poly(dimethylsiloxane) and poly(styrene), allowing their 
integration with the wide range of microscopic technologies previously discussed. Although still in its 
infancy, tissue-like microfluidic-based platforms already proved the ability to emulate different in 
vivo conditions. Examples include their application to mimic vascular, cardiac, renal, pulmonary and 
hepatic interfaces ([22] for a review). Some of these tissue-like microfluidic platforms were already 
used to study nanoparticle–cell interaction [23,24], as well as nucleic acid delivery [25] with predictive 
outcomes for the in vivo application. But their full applicability to explore and optimize drug and 
nucleic acid delivery systems is yet to be reached. 
‘Visualizing’ the future 
The dissection of nanoparticle–cell interaction mechanisms and the assessment of their distribution 
and fate at the subcellular level are of great importance since these events can give us cues about 
their effect/action on cells and aid in the definition of key requirements for nanoparticle design and 
preparation. Due to its unique features, microfluidics are more and more prominent in the 
nanomedicine field and in the assessment of biofunctionality of nanoparticle-based vectors. The 
combination of microfluidic platforms together with the application of new (quantitative) bioimaging 
tools will accelerate the progress of preclinical nanoparticle studies contributing to a more educated 
and focused advance of the field and bringing to the light of day of the long-awaited benefits. 
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